Nuvectis Pharma, Inc. Quarterly Return On Equity in % from Q4 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Nuvectis Pharma, Inc. quarterly/annual Return On Equity history and growth rate from Q4 2021 to Q3 2024.
  • Nuvectis Pharma, Inc. Return On Equity for the quarter ending September 30, 2024 was -156 %, a 10.8% decline year-over-year.
  • Nuvectis Pharma, Inc. annual Return On Equity for 2023 was -145 %, a 15% decline from 2022.
  • Nuvectis Pharma, Inc. annual Return On Equity for 2022 was -126 %, a 159% decline from 2021.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q3 2024 -156 -15.1 -10.8% Jul 1, 2024 Sep 30, 2024
Q2 2024 -152 -19.3 -14.6% Apr 1, 2024 Jun 30, 2024
Q1 2024 -142 -3.19 -2.31% Jan 1, 2024 Mar 31, 2024
Q4 2023 -145 -18.9 -15% Oct 1, 2023 Dec 31, 2023
Q3 2023 -141 +24.8 +15% Jul 1, 2023 Sep 30, 2023
Q2 2023 -133 +746 +84.9% Apr 1, 2023 Jun 30, 2023
Q1 2023 -138 -785 -121% Jan 1, 2023 Mar 31, 2023
Q4 2022 -126 -337 -159% Oct 1, 2022 Dec 31, 2022
Q3 2022 -165 Jul 1, 2022 Sep 30, 2022
Q2 2022 -879 Apr 1, 2022 Jun 30, 2022
Q1 2022 647 Jan 1, 2022 Mar 31, 2022
Q4 2021 212 Oct 1, 2021 Dec 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.